NCT00554411

Assessing Ocular Surface Changes After Changing Glaucoma Medications

Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 22 (actual)
• Sponsor: University of Colorado, Denver · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Detailed description

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

Conditions

• Glaucoma
• Monotherapy With Xalatan From 1 to 18 Months
• Ocular Surface Disease

Timeline

• Start date: 2007-11-01
• Primary completion: 2011-08-01
• Completion: 2011-08-01
• First posted: 2007-11-06
• Last updated: 2017-01-27

Locations

1 site across 1 country: United States